# Tranexamic Acid During Cystectomy Trial (TACT)

> **NCT01869413** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 354 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Tranexamic Acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01869413
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2021-01
- **Final completion:** 2021-06
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2022-10-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01869413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01869413, "Tranexamic Acid During Cystectomy Trial (TACT)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01869413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*